complement-mediated disorders | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

40,306 results for “complement-mediated disorders”

Trials

View all 33592 →

Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders

122 participants · First posted Jul 20, 2015

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

50 participants · First posted Oct 20, 2017

Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation

16 participants · First posted Apr 1, 2011

Drugs

View all 428 →

factor D inhibitors (complement-mediated diseases)

MASP-2 inhibitors (lectin disorders/ Complement pathways disorders)

MASP-2/3 inhibitors (lectin disorders/ Complement pathways disorders)

Organizations

View all 97 →

Annexon

United States

Institute For Neurodegenerative Disorders

United States

Ascendis Pharma Growth Disorders A/S

Denmark

News

View all 6189 →

Ruxoprubart Shows Promising Phase II Results as Novel Monotherapy for Paroxysmal Nocturnal Hemoglobinuria

Ruxoprubart Achieves Primary Endpoints in Phase 2 Trial for Paroxysmal Nocturnal Hemoglobinuria

Novartis' FABHALTA Poised to Transform Treatment Landscape for Multiple Complement-Mediated Diseases

Page 1 of 4031